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Abstract
Background: Non-union of fractured bone is a major cause of morbidity in the orthopaedic population. Despite
this, optimal management of non-union is still unclear and remains a significant clinical challenge. Research
continues in animal models in an attempt to identify an effective clinical treatment. The proposed systematic
review will evaluate current therapies of bone non-union in animal models, in order to identify those that may
translate successfully to clinical therapies.
Methods/design: The methodology for the systematic review will be in accordance with standard guidelines. All potential
sources for pre-clinical studies will be interrogated and the search strategy written in conjunction with a specialist in this
field. Data extraction will be conducted by two reviewers to minimise bias. Analysis will be predominantly qualitative
because of the heterogeneity that is likely to exist between the studies. However, quantitative synthesis will be performed
where homogeneity in a sub-group of studies exists. Quality assessment will be undertaken utilising a risk of bias tool.
Discussion: To date, there has not been a systematic review addressing bone non-union therapies in animal models
despite the plethora of pre-clinical research currently being undertaken. This protocol details and outlines the
methodology and justification for such a review.
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Background
Non-union is a condition where fractured bone does not
heal. This can result in delayed recovery, re-hospitalisation,
unplanned revision surgery and potentially, limb amputa-
tion [1, 2]. The rate of non-union can be as high as 30 % in
the most severe injuries seen in the civilian setting,
rising to 50 % when seen in injuries caused by mili-
tary weapons [1–3].
A number of therapies including electromagnetic field
stimulation, ultrasound, shockwave intervention, and bone
morphogenetic protein therapy have been tested in the
clinical setting, aimed at preventing or treating non-union.
Moreover, they have been evaluated in meta-analysis of
clinical trials [4–7]. However, these meta-analyses reveal
that there is limited evidence of the efficacy of these
therapies. Pre-clinical and translational work utilising ani-
mal models to develop more potent treatments therefore
continues.
Animal models eliminate the confounders that beset
clinical work, through standardisation of conditions within
a model. However, there is little standardisation between
models used by different researchers with a breadth of
methodologies and outcome measures being employed to
evaluate models of bone non-union [8–11]. Current pre-
clinical work investigating new therapies for promoting
bone healing is prolific, as identified in a scoping search of
primary studies. Novel strategies that have yet to translate
to clinical studies include integrating stem cells into a
polymer scaffold embedded with hydroxyapatite particles
to stimulate bioactivity [12], use of other growth factors
such as stromal-cell derived factor and transforming growth
factor to augment the effects of bone morphogenetic pro-
teins [13], and novel synthetic bone substitutes [14].
* Correspondence: sarah_stewart86@hotmail.com
1Royal Centre for Defence Medicine, Queen Elizabeth Hospital, Birmingham
B15 2THWest Midlands, UK
Full list of author information is available at the end of the article
© 2015 Stewart et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Stewart et al. Systematic Reviews  (2015) 4:161 
DOI 10.1186/s13643-015-0148-6
To date, there has been no work to systematically
examine and compare all the current pre-clinical and
translational evidence to prevent and treat non-union,
which is yet to be evaluated in clinical trials. Here, we
present a protocol for a systematic review investigating the
clinical challenge of bone non-union in animal models.
Objective
To systematically collect and analyse published and un-
published evidence of therapies for preventing and treating
non-union, which are yet to be translated to clinical trials.
Methods
This protocol was written in accordance with the pre-
ferred reporting items for systematic reviews and meta-
analysis protocols (PRISMA-P) guidelines [15]. Reporting
of the full systematic review will take into account both the
PRISMA guidelines [16] and guidelines specific for system-
atic reviews of animal studies [17]. The protocol has been
registered and published on Collaborative Approach to
Meta Analysis and Review of Animal Data from Experi-
mental Studies (CAMARADES). The protocol was not reg-
istered with PROSPERO, as reviews on animal models were
not eligible for inclusion at the time of writing.
Searches
The following sources will be searched for primary studies:
 Bibliographic databases—PubMed and Embase
via Ovid.
 The Science Citation Index for citation searching.
 The British Library’s Zetoc research database.
 Hand searching citation lists of included studies and
relevant reviews.
 Hand searching of relevant conference proceedings
i.e. Orthopaedic Research Society, Orthopaedic
Trauma Association, Experimental Biology, Tissue
Engineering and Regenerative Medicine Society.
 Contact with study authors and researchers of
ongoing trials.
A combination of text and index terms relating to the
condition (bone non-union) and population (animal model)
will be used. Terms relating to intervention (e.g. stem cells,
shock waves) will not be included. This is justified as emer-
ging therapies for bone non-union are likely to be so novel
that eligible papers may be missed in the search if interven-
tion terms are included. Although this will undoubtedly
produce a high yield of studies from the search, the sensi-
tivity of the search (and therefore comprehensiveness of the
systematic review) will be improved.
A filter for the retrieval of animal studies as described by
de Vries et al. [18, 19] will be utilised. These have been
shown to retrieve greater numbers of animal studies than
the standard search filters on these engines. Language
restrictions will not be applied. A date restriction
(2004–present) will be applied. Justification for this de-
cision stems from the likelihood that studies conducted
prior to 2004 will either have already translated to clinical
research (rendering them ineligible for inclusion in the
systematic review), or found to confer insufficient benefit
to warrant translation to the human population. An ex-
ample search strategy is included in Additional file 1.
An electronic database (EndNote version X7.1, Thomson
Reuters, New York) will be used to store and manage
search results, regardless of whether the studies are eventu-
ally included or excluded in the systematic review. Titles
and abstracts generated from the search will be screened by
two reviewers (SKS/PMB) in order to establish if they po-
tentially meet the inclusion criteria. Full articles will be
obtained for all records that are identified as potentially
meeting the inclusion criteria, or where there is uncer-
tainty. Two reviewers (SKS/PMB) will independently
screen and evaluate full text reports against the inclusion
criteria. Differing of opinions between the two reviewers
will be resolved by discussion with a third reviewer (JPB).
Where ambiguity remains, contact with the study’s authors
will be attempted to clarify issues pertaining to eligibility
for the systematic review. Papers in languages other than
English, whose abstracts indicate that they may meet the
inclusion criteria, will be translated in full or in part. A
PRISMA flow diagram will be used to document the study
selection process, and a record of excluded studies (includ-
ing reasons for exclusion) will be kept.
Selection criteria
Types of studies
Only controlled trials will be eligible for inclusion. In
vitro experiments, cohort studies, case reports, reviews
and letters will be excluded. Given the nature and ease
of randomisation in animal studies, it is likely that the
majority of studies generated from the searches will be
randomised controlled trials. Both unpublished and pub-
lished works are eligible for inclusion.
Types of participants
Eligible studies must use a mammalian model to test an
intervention to treat or prevent bony non-union. There
will be no restrictions placed on the anatomical site of the
bony defect created. Studies with induced co-morbidities
(e.g. immunosuppression, osteoporosis) in the animal sub-
ject will be included.
Intervention
The study assesses an intervention in a mammalian animal
model intended to
 Prevent non-union
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 Treat non-union
 Promote or accelerate healing of a bony defect
 Treat or ameliorate delayed union
The intervention must be administered after formation of
a bony defect in an animal model. There may be studies
that test an established intervention but delivered to the ani-
mal model through a novel vehicle. These will be included
as they may represent a more effective treatment modality.
Comparator
A group of control animals are described, which receive
 No treatment
 Current standard of care for the insult in question
 An alternative treatment to the intervention being
analysed
Outcome measures
The primary outcome of interest is bone formation. A
quantifiable measure of bone formation must therefore be
assessed (morphometrical analysis). This can be achieved
through radiological means and/or histological means.
Secondary outcomes of interest will be related to the
structural properties of the newly formed bone (biomech-
anical analysis), which may include:
 Indentation testing
 Microtensile and microcompressive analysis
 Three- and four-point bending
Papers that perform biomechanical analysis (secondary out-
comes) in the absence of morphometrical analysis (primary
outcomes) will not be included in the systematic review.
Exclusion of therapies with evidence of clinical evaluation
The stated intention of this study is to examine emerging
therapies that have not yet been evaluated clinically. To
that end, studies describing therapies that have translated
into clinical studies will be filtered. The authors will ex-
clude all papers detailing interventions that they know are
already in clinical trials or indeed being used in clinical
practice. Where uncertainty exists, the following steps will
be performed prior to data extraction:
 PubMed and Embase will be searched for clinical
studies that cite each study that otherwise meets
the inclusion criteria.
 PubMed and Embase will be searched using keywords
describing the specific therapies for studies describing
clinical evaluation.
All studies describing therapies that are found to
have been evaluated clinically will be excluded, and
the results of this ‘clinical filter’ will added to the
PRISMA flow chart.
Data extraction
A proforma detailing the necessary information to be ex-
tracted from the eligible articles has been designed
(Additional file 2). The proforma will be piloted by the
two reviewers (SKS/PMB) prior to commencing the data
collection formally. This will serve to not only test the
efficacy of the proforma itself, but also calibrate the re-
viewers to ensure consistency. Information required (but
not limited to) from each study is detailed in Table 1.
Missing data
During proforma completion, we will seek missing data
that is required for analysis from the original study author.
If a study does not mention an item detailed on the data
collection form and the review authors are unable to obtain
the information, its absence will be noted and presumed
not to have been performed (e.g. no mention of randomisa-
tion will be presumed that it was not performed). This
Table 1 Suggested data to be extracted from eligible papers
Publication details Authors, year of study, year of publication,
geographical location of study, language of
paper, funding sources
Study design and
quality
Sample size, p values, methods to randomise,
allocation concealment, blinding of
outcome assessment.
Model of non-union Non-union vs delayed union
Species of animal Mouse, rat, etc.
Characteristics of animal Age, weight, strain, sex, genetic modification,
co-morbidities
Nature of insult Location of bony insult (tibia, femur, etc.),
fracture model (segmental vs non-segmental),
osteotomy technique, size of osteotomy, closed
vs open, critical vs non-critical size defect,
fixation vs no fixation, internal vs external
fixation (if fixation used), isolated or
multiple locations,
Additional insults (other
than bony defects)
Infection, contamination, immunosuppression,
soft tissue injury, vascular injury.
Nature of intervention Type of intervention (pharmacological vs
non-pharmacological), time point that
intervention was applied to animal model
post-fracture creation, frequency of
intervention (single vs recurrent), duration
of intervention, systemic or local dosing
Duration of follow-up Single vs multiple time points of follow-up
Outcome measures Morphometrical analysis (e.g. histology,
radiology), biomechanical analysis
(e.g. torsional stiffness)
Results Main findings, direction of effect, effect sizes
and uncertainty, statistical significance, length
and adequacy of follow-up, early animal death
Additional insults (other
than bony defects)
Infection, contamination, immunosuppression,
soft tissue injury, vascular injury.
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domain will be labelled as ‘high risk’ and its consequential
impact on the validity of the study will be assessed when
conducting risk of bias assessment (see below).
Quality assessment
Potential bias within the pre-clinical studies will be deter-
mined by the reviewers prior to analysis. Both the
Cochrane Collaboration tool [20] and Systematic Review
Centre for Laboratory animal Experimentation’s (SYRCLE)
risk of bias tool [21] which is specific for animal studies will
be used. Criteria such as sequence generation, allocation
concealment, blinded outcome assessment and incomplete
outcome data (e.g. animals that died prematurely) will be
identified and recorded, and each domain given a rating of
‘high risk’ or ‘low risk’ based on the details provided in the
literature. Where information is missing, the domain will
be labelled as ‘unclear’.
Analysis
Results from this systematic review will be presented in
the form of a narrative synthesis. Key study characteris-
tics such as animal species, intervention and results will
be tabulated to aid clarity of study findings.
In the instance where homogeneity exists between a
number of studies, quantitative synthesis will be attempted
using Review Manager (RevMan v5.3) software. Whilst the
generation of pooled effect sizes may not be as meaningful
compared to ones provided by clinical trials, meta-analyses
of animal studies may still be useful for showing the over-
all direction of effect and the heterogeneity across studies.
Moreover, they may serve to generate hypotheses [22].
Sub-group analysis
Sub-group analysis will be considered where studies can
be grouped according to the following characteristics:
 Animal species (e.g. mice, rats, other mammalian
species)
 Animal sex (e.g. male, female, mixed)
 Experimental intervention used (e.g. autografts,
allografts, synthetic)
 Delivery of experimental intervention (e.g. oral,
intravenously, directly to fracture site).
 Nature of defect created (critical or non-critical defect)
 Models of non-union (hypertrophic or atrophic)
 Models of delayed union versus non-union
 Prevention versus treatment of non-union
 Application of an insult (e.g. osteoporosis, infection,
diabetes)
 Methodological quality according to Cochrane risk
of bias tool (e.g. by individual domain)
It is recognised that a large number of sub-group ana-
lyses on small numbers of studies may affect the power
of the analyses; should this be the case here, any findings
from sub-group analyses will have to be interpreted cau-
tiously. Presentation of (separate sets of) results in forest
plots without the calculation of a summary measure may
also be considered in order to highlight any heterogeneity
across studies.
Effect measures for continuous outcomes
The primary outcome measure is bone formation. This will
predominantly be in the form of continuous data, for ex-
ample, bone mass densities (mg m−2). In these instances,
the mean difference between formation of bone in the ex-
perimental and control groups will likely be presented, and
forest plots can be used to show the pooled mean differ-
ence. The standardised mean difference may also be used
in instances where papers are measuring the same out-
come, e.g. bone density, but using different modalities
to achieve this, e.g. micro-CT, photon emission CT, and
X-ray.
Effect measures for dichotomous outcomes
In studies which present dichotomous data, the relative
risk may be presented and meta-analysis may enable the
calculation of a pooled relative risk. A situation where
this could occur is analysis of whether bone formation
did or did not occur at a set time point. In studies which
measure the time to the formation of new bone in the in
vivo model, i.e. time-to-event data, the pooled hazard ra-
tio may be calculable.
Given that residual heterogeneity is anticipated even be-
tween studies considered to be similar enough to pool, a
random effects model (as opposed to a fixed effects model)
is more likely to be appropriate for meta-analysis. A ran-
dom effects model will therefore be used for quantitative
analysis of dichotomous data. A random effects model has
been chosen because it is based on the assumption that al-
though the studies are different, they are estimating differ-
ent, yet related intervention effects. If heterogeneity does
exist, it will lead to a wider confidence intervals and there-
fore corresponding claims of statistical significance will be
more conservative [23]
A decision on whether to pool will be made on the basis
of an assessment of clinical and methodological hetero-
geneity. However, statistical heterogeneity will also be re-
ported using the I2 statistic and the χ2 test. The likelihood
of publication bias will be investigated through the con-
struction of funnel plots for each meta-analysis containing
ten or more studies.
Assessment of bias
Assessing and analysing risk of bias will be an important
component of the systematic review. Criteria determining
the likelihood of bias will be collected as described above
(see ‘Quality Assessment’) and a ‘risk of bias graph’ used to
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illustrate where bias predominates across studies. This will
serve to inform the authors of where caution must be
heeded when analysing the data. It is anticipated that a nar-
rative discussion on the risk of bias will be incorporated
into the review, included in which will be discussion on do-
mains which consistently displayed ‘low’, ‘high’ or ‘unclear’
risk. Analysis as to why this may be the case and how this
could affect translation of the pre-clinical trial to clinical
trials will be discussed.
Where quantitative analysis of subgroups is possible, the
threshold based on key bias domains that have been iden-
tified during the initial trawl will determine which studies
are eligible for inclusion into the subgroup analysis. Key
bias domains are derived from the CAMARADES qual-
ity checklist for animal studies [24], and include seven
domains:
 Publication in peer reviewed journal
 Randomisation of treatment or control
 Allocation concealment
 Blinded assessment of outcome
 Sample-size calculation
 Statement of compliance with regulatory
requirements
 Statement regarding possible conflict of interest
It is anticipated that studies at low risk of bias for the
key domains will not be combined with studies at high
or unclear bias for meta-analysis. In the event where
such a priori criteria generate insufficient studies to per-
form quantitative analysis, pooling of studies regardless
of bias risk may have to occur. In this instance, authors
will highlight the reasoning for this in the review to en-
sure transparency of results.
Control group bias
Due care in data synthesis must also be paid when stud-
ies share control groups between experimental groups.
For example, a study may have a single control group
but three different experimental groups with varying
sizes of segmental defects created. When such compari-
sons are made, animals in the control group are essen-
tially counted three times and the comparisons will
receive too much weight in the estimation of summary
effect [22]. Techniques such as splitting the control
group to equalize the number of experimental groups
before performing analysis [23], will be used to mitigate
against this potential source of bias.
Discussion
Systematic reviews of pre-clinical studies enable ap-
praisal and analysis of potential treatments prior to
translation to human studies. Although this protocol de-
tails the methodology for a systematic review of pre-
clinical studies investigating bone non-union, other clin-
ical challenges can use such an approach to the same
effect.
In the absence of a widely established, effective treat-
ment for bone non-union, and a lack of systematic reviews
of all potentially relevant emerging treatments from the
pre-clinical field, a new systematic review is clearly war-
ranted. It is likely that this will be the most comprehensive
to date in the area of novel and emerging treatments for
bone healing.
A recent review by Mills and Simpson [11] examined
the heterogeneity that exists between animal models for
non-union, identifying a number of clinical scenarios
which animal studies aim to reproduce. Even within sub-
groups of outwardly similar study designs, the variability
between studies was extensive. As such, careful consid-
eration and differentiation of the experimental question
of studies included in the review is required. Based on
their review, the following recommendations are sug-
gested when sub-grouping papers for analysis.
Of particular note, delayed union is a distinct entity and
must be differentiated from non-union in the systematic
review to ensure transparency of analysis. Delayed union is
prolonged bony healing compared to that of a control
group, and will often be the pre-cursor to a non-union
model. Unlike a model of non-union where the occurrence
of such a defect can be objectively assessed at a set time
point, delayed union is a clinical diagnosis with no defined
criteria for assessment. Due to the fundamental differences
in the definition of delayed union and non-union, separate
syntheses will be performed.
Models where a segmental defect has been established
should be considered separately to those where there is no
iatrogenic bone removal. Attention during data synthesis is
also required for models which involve high-energy trauma,
open or comminuted fractures, and introduction of infec-
tion or immunocompromise, in addition to an intervention
intended to treat or prevent non-union. For the purposes
of meta-analyses, studies where there has been introduc-
tion of such an insult will be analysed separately and not
combined with studies where an insult has not been intro-
duced. Inclusion of an insult in an animal model of non-
union will inherently produce higher rates of delayed and
non-union, compared with those models where there is an
intervention alone.
Finally, it is important to consider the difference be-
tween atrophic and hypertrophic models of non-union.
Atrophic models are characterised by a failure of peri-
osteal and endosteal activity, with minimal callus for-
mation. Hypertrophic non-union is less common, and
is typified by high callus formation and endochondral
growth at the fracture sites. Given their contrasting
pathophysiological processes, studies with hypertrophic
and atrophic models will not be synthesised together.
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As demonstrated in Mills and Simpson’s review, the
heterogeneic nature of animal models will likely hamper
interpretation of results across all studies. Variations in
species, methodology and study characteristics may also
limit the number of trials considered similar enough to
meta-analyse, and sub-group analyses within these sets of
studies may also not be possible. However, it is anticipated
that by presenting all the available pre-clinical evidence, it
will be possible to observe trends for effectiveness for one
or more emerging techniques. Pooled effect sizes may not
be meaningful in terms of their applicability to human
populations, and any findings must be interpreted in the
context of study quality and the extent to which they are
considered translatable to other settings. However, this
systematic review will be valuable for hypothesis generat-
ing and may be able to aid in the identification of suitable
candidate treatments to take forward into clinical trials.
Accurate and valid hypotheses can consequently be drawn
as to which emerging therapies for bony non-union may
translate successfully to the human population.
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